TG THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.92 USD | -1.17% |
|
+3.05% | -0.94% |
| May. 01 | Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts | MT |
| May. 01 | Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024 |
Presenter SpeechAlec Stranahan (Analysts)Good afternoon, and welcome to day 1 of the 2023 BofA...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Brutonâs tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Calendar
2024-06-14
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
16.92
USD
Average target price
31.5
USD
Spread / Average Target
+86.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.94% | 2.42B | |
| +23.37% | 47.02B | |
| +49.79% | 41.86B | |
| -0.94% | 41.76B | |
| -4.27% | 28.8B | |
| +11.29% | 26.05B | |
| -20.92% | 19.15B | |
| +3.20% | 12.55B | |
| -2.67% | 11.82B | |
| +30.23% | 12.34B |
- Stock Market
- Equities
- TGTX Stock
- News TG Therapeutics, Inc.
- Transcript : TG Therapeutics, Inc. Presents at Bank of America Securities 2023 Healthcare Conference, May-09-2023 03